This National HIV/AIDS Strategy (the Strategy), the nation’s third national HIV strategy, updates the HIV National Strategic Plan (2021). The Strategy sets forth bold targets for ending the HIV epidemic in the United States by 2030, including a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030
Recent news about HIV biomedical prevention research has been a mixed bag: very encouraging results from long-acting pre-exposure prophylaxis (PrEP) trials, but a disappointing lack of significant protection achieved with experimental HIV vaccines. Furthermore, the entire research effort has had to wrestle with the impact of the COVID-19 pandemic.
Este resumen ofrece un panorama general de la profilaxis de post-exposición (PEP) al virus VIH (virus de inmunodeficiencia humana)
This brief provides an overview of HIV Post-exposure Prophylaxis (PEP) in the southern United States (“the South”). The goal is to provide an overview of prevention with PEP to drive collective action between: Jurisdictional and local public health departments, community-based organizations (CBOs), and community health clinics, to increase and improve prevention with PEP.
This report highlights factors other than individual attributes related to sex, race/ethnicity, or behavioral risk factors that contribute to disparities among people living with HIV.
This report highlights policies and programs that are critical to effective biomedical HIV prevention in communities of color.
The information included in this report provide preliminary data on HIV diagnoses and linkage to HIV medical care reported to CDC as of June 2020 for the years 2019 and 2020.
This slide set analyzes trends in rates and distributions of deaths in the United States.
This report provides diagnoses of HIV infection among adolescents and young adults in the United States and 6 Dependent areas.
This report provide preliminary data on HIV diagnoses and linkage to HIV medical care for the year 2019.
